Voor zorgverleners

Sanofi at ESC Congress 2026 | ASCVD & LDL-C Management

Discover how you can help change the trajectory of ASCVD.

Uncontrolled CRSwNP: Position of Advanced Therapy

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic, type 2 inflammatory disease that often remains uncontrolled despite standard medical and surgical treatment. According to the international EUFOREA definition, uncontrolled CRSwNP is defined by¹:   1. Patient-reported lack of control and  2. Clinically relevant symptoms of active disease

Nieuw: Landelijke prijsafspraak Dupixent®

Wat betekent dit voor u en uw ziekenhuis?

Ontdek wat het NCEP voor u kan betekenen

Het Nationaal Constitutioneel Eczeem Project (NCEP) biedt praktische materialen, tools en nascholingen aan op eczeemwijzer.nl om zorgprofessionals te ondersteunen bij de zorg voor mensen met constitutioneel eczeem.

RELIBIO: Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis

Dupilumab's* efficacy and safety in severe CRSwNP was established in the LIBERTY NP SINUS-24 and SINUS-52 randomized, double-blind, placebo-controlled phase 3 trials, and is reflected in the approved SmPC.^1,2 As real-world context to this robust RCT evidence, the observational RELIBIO study** provides additional insight into clinical effectiveness, treatment response, and switching patterns among 360 patients with severe CRSwNP treated with dupilumab (n=53), omalizumab (n=65) and mepolizumab (n=242) in routine Belgian clinical practice.³

Dupixent - AD

DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling, targeting an important mechanism of inflammation common across a range of skin diseases.

Chronische Rhinosinusitis met Nasale Poliepen (CRSwNP): De verbinding tussen Type 2 Inflammatie en Reukverlies

Unstoppable commitment to ASCVD care for over 10 years

The Importance of Lung Function in Severe Asthma - A Clinical Perspective